Your browser doesn't support javascript.
loading
Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies.
Inada, Makoto; Ishikane, Masahiro; Terada, Mari; Matsunaga, Akihiro; Maeda, Kenji; Tsuchiya, Kiyoto; Miura, Kenji; Sairenji, Yu; Kinoshita, Noriko; Ujiie, Mugen; Kutsuna, Satoshi; Ishizaka, Yukihito; Mitsuya, Hiroaki; Ohmagari, Norio.
Afiliação
  • Inada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ishikane M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.
  • Terada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Matsunaga A; Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Maeda K; Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tsuchiya K; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Miura K; Department of Respiratory Medicine, Yokohama Sakae Kyosai Hospital, Kanagawa, Japan.
  • Sairenji Y; Department of Respiratory Medicine, Yokohama Sakae Kyosai Hospital, Kanagawa, Japan.
  • Kinoshita N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ujiie M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kutsuna S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ishizaka Y; Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Mitsuya H; Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
J Infect Chemother ; 27(7): 1063-1067, 2021 Jul.
Article em En | MEDLINE | ID: mdl-33962861
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: J Infect Chemother Assunto da revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: J Infect Chemother Assunto da revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão